Statinum
 |
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt. |
Statina, inhibitores quoque HMG-CoA reductasis notae, sunt grex lipoproteina minuentia, ideo hyperlipidaemiarum tractationis idonee, medicamentorum.
Varia statina adhibentur, ut Atorvastatinum, Lovastatinum, Pravastatinum, Simvastatinum.
Machinatio statinorum
[recensere | fontem recensere]
Statina enzymum hydroxy-methylo-glutarylo-coenzymi-A reductasis (HMG-CoA reductasis) inhibitores competitivi obsident. Eo modo statina cholesteroli synthesem inhibent, multitudo LDL in sanguine minuent. Non pronuper investigatores effectus adversarios ad metabolismum spectare quoque monebant, imprimis ad myopathiam statinis[1].
HMG-CoA reductasis
[recensere | fontem recensere]3-Hydroxy-3-methylo-glutarylo-coenzymi A reductasis est a NADH et NADPH dependens enzymum intra iter metabolicum acidi mevalonati, cuius duo producta sunt isopentenyli pyrophosphatum (IPP) et dimethyloallyli pyrophosphatum (DMAPP). Ambo formationis terpenoidorum (seu isoprenoidorum) necesse sunt, propterea terpenoida nidamentum plus quam 30,000 substantiarum chemicarum servant, non solum cholesteroli sed aliarum ut haemis, vitamini K, coenzymi Q10 et omnium hormontum steroidalium[2].
Effectus non grati
[recensere | fontem recensere]Myopathia statinis sociata
[recensere | fontem recensere]Interdum hebdomadibus vel mensibus paucis, quo statinum consumebatur, imbecillitas musculorum observatur. Imbecillitas haec, myopathia dicta, motus corporis impedire queat, etiam renum functionem, si rhabdomyolysis (dissolutio structurarum musculorum) saeviat. Symptomata gravissima vel discontinuationem medicamenti pernecesse faciendi iubeat[3].
Substantiae
[recensere | fontem recensere]| Statinum | Metabolimus | Semivita (h) |
|---|---|---|
| Atorvastatinum | CYP3A4 | 14—19 |
| Fluvastatinum | CYP2C9 | 1—3 |
| Lovastatinum | CYP3A4 | 1—3 |
| Pravastatinum | non CYP | 1—3 |
| Rosuvastatinum | CYP2C9, CYP2C19 |
14—19 |
| Simvastatinum | CYP3A4 | 1—3 |
Nexus interni
Notae
[recensere | fontem recensere]- ↑ Ahmadi Y, Ghorbanihaghjo A, Naghi-Zadeh M, Yagin NL (2018). "Oxidative stress as a possible mechanism of statin-induced myopathy". Inflammopharmacology
- ↑ Holstein SA, Hohl RJ (2004). "Isoprenoids: remarkable diversity of form and function". Lipids 39 (4): 293-309
- ↑ Tomaszewski M., Stępień K.M., et al. (2011). "Statin-induced myopathies". Pharmaclogical reports 63 (4): 859-66
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
